Literature DB >> 19286092

Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries.

Kornelia Kotseva1, David Wood, Guy De Backer, Dirk De Bacquer, Kalevi Pyörälä, Ulrich Keil.   

Abstract

BACKGROUND: The first and second EUROASPIRE surveys showed high rates of modifiable cardiovascular risk factors in patients with coronary heart disease. The third EUROASPIRE survey was done in 2006-07 in 22 countries to see whether preventive cardiology had improved and if the Joint European Societies' recommendations on cardiovascular disease prevention are being followed in clinical practice.
METHODS: EUROASPIRE I, II, and III were designed as cross-sectional studies and included the same selected geographical areas and hospitals in the Czech Republic, Finland, France, Germany, Hungary, Italy, the Netherlands, and Slovenia. Consecutive patients (men and women </=70 years) were identified after coronary artery bypass graft or percutaneous coronary intervention, or a hospital admission with acute myocardial infarction or ischaemia, and were interviewed at least 6 months later.
FINDINGS: 3180 patients were interviewed in the first survey, 2975 in the second, and 2392 in the third. Overall, the proportion of patients who smoke has remained nearly the same (20.3% in EUROASPIRE I, 21.2% in II, and 18.2% in III; comparison of all surveys p=0.64), but the proportion of women smokers aged less than 50 years has increased. The frequency of obesity (body-mass index >/=30 kg/m(2)) increased from 25.0% in EUROASPIRE I, to 32.6% in II, and 38.0% in III (p=0.0006). The proportion of patients with raised blood pressure (>/=140/90 mm Hg in patients without diabetes or >/=130/80 mm Hg in patients with diabetes) was similar (58.1% in EUROASPIRE I, 58.3% in II, and 60.9% in III; p=0.49), whereas the proportion with raised total cholesterol (>/=4.5 mmol/L) decreased, from 94.5% in EUROASPIRE I to 76.7% in II, and 46.2% in III (p<0.0001). The frequency of self-reported diabetes mellitus increased, from 17.4%, to 20.1%, and 28.0% (p=0.004).
INTERPRETATION: These time trends show a compelling need for more effective lifestyle management of patients with coronary heart disease. Despite a substantial increase in antihypertensive and lipid-lowering drugs, blood pressure management remained unchanged, and almost half of all patients remain above the recommended lipid targets. To salvage the acutely ischaemic myocardium without addressing the underlying causes of the disease is futile; we need to invest in prevention.

Entities:  

Mesh:

Year:  2009        PMID: 19286092     DOI: 10.1016/S0140-6736(09)60330-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  164 in total

1.  Randomized controlled trial on the long-term efficacy of a multifaceted, interdisciplinary lifestyle intervention in reducing cardiovascular risk and improving lifestyle in patients at risk of cardiovascular disease.

Authors:  Lysanne Goyer; Robert Dufour; Caroline Janelle; Chantal Blais; Christine L'Abbé; Emilie Raymond; Jacques de Champlain; Pierre Larochelle
Journal:  J Behav Med       Date:  2012-03-09

2.  How to promote exercise in primary care.

Authors:  Helena Liira
Journal:  Scand J Prim Health Care       Date:  2010-09       Impact factor: 2.581

Review 3.  The optimal blood pressure target for patients with coronary artery disease.

Authors:  Paolo Verdecchia; Fabio Angeli; Claudio Cavallini; Giovanni Mazzotta; Marta Garofoli; Paola Martire; Gianpaolo Reboldi
Journal:  Curr Cardiol Rep       Date:  2010-07       Impact factor: 2.931

Review 4.  Polypill: lights and shadows.

Authors:  Koon K Teo; Yan Liang
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

5.  Is Optimal Medical Therapy as Used in the COURAGE Trial Feasible for Widespread Use?

Authors:  David J Maron; William E Boden; William S Weintraub; Karen J Calfas; Robert A O'Rourke
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-02

6.  Implementation of Cardiovascular Disease Prevention Guidelines in Clinical Practice-Can We Do Better?

Authors:  Kornelia Kotseva
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-12

7.  Trends in cardiovascular risk factors among patients with coronary heart disease: results from the EUROASPIRE I, II, and III surveys in the Münster region.

Authors:  Christof Prugger; Jan Heidrich; Jürgen Wellmann; Ralf Dittrich; Stefan-Martin Brand; Ralph Telgmann; Günter Breithardt; Holger Reinecke; Hans Scheld; Peter Kleine-Katthöfer; Peter U Heuschmann; Ulrich Keil
Journal:  Dtsch Arztebl Int       Date:  2012-04-27       Impact factor: 5.594

8.  Negotiating substance use stigma: the role of cultural health capital in provider-patient interactions.

Authors:  Jamie Chang; Leslie Dubbin; Janet Shim
Journal:  Sociol Health Illn       Date:  2015-09-18

Review 9.  Socioeconomic status and cardiovascular disease: risks and implications for care.

Authors:  Alexander M Clark; Marie DesMeules; Wei Luo; Amanda S Duncan; Andy Wielgosz
Journal:  Nat Rev Cardiol       Date:  2009-09-22       Impact factor: 32.419

10.  [European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. CEIPC 2008 Spanish Adaptation].

Authors:  José M A Lobos Bejarano; Miguel Angel Royo-Bordonada; Carlos Brotons; Luís Alvarez-Sala; Pedro Armario; Antonio Maiques; Dídac Mauricio; Susana Sans; Fernando Villar; Angel Lizcano; Antonio Gil-Núñez; Fernando de Alvaro; Pedro Conthe; Emilio Luengo; Alfonso Del Río; Olga Cortés; Ana de Santiago; Miguel A Vargas; Mercedes Martínez; Vicenta Lizarbe
Journal:  Aten Primaria       Date:  2009-07-15       Impact factor: 1.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.